Last Updated : October 18, 2024
Details
Generic Name:
semaglutide
Project Status:
Pending
Therapeutic Area:
weight management
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Wegovy
Project Line:
Reimbursement Review
Project Number:
SR0841-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of equal to or greater than 27 kg/m2 and established cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease).
Submission Type:
Resubmission
Fee Schedule:
Pending
Indications:
Wegovy (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 18, 2024